Richard Hazan Kumet
- Assistant Professor, Psychiatry - (Clinical Scholar Track)
- (520) 626-6336
- AHSC, Rm. 7429
- TUCSON, AZ 85724-5002
- rkumet@arizona.edu
Biography
Dr. Kumet currently serves as the Assistant Chief, of the Mental Health Care Line at the Southern Arizona VA Healthcare System (SAVAHCS). He has been on facutly at SAVAHCS since graduating from the University of Arizona Health Sciences Center Adult Psychiatry Residency Program in 2003. Dr. Kumet provides psychiatric care to Veterans at SAVAHCS. Additionally he serves as liaison of Psychiatry Residency Training at SAVAHCS and works closely with the Banner University Psychiatry Residency Training Program in this role. Dr. Kumet also regularly gives lectures to third year medical students at the University of Arizona College of Medicine as they rotate through their psychiatry clerkship. In addition, Dr. Kumet serves as a mentor to third medical students on this clerkship. Dr. Kumet is Board Certified by the American Board of Psychiatry and Neurology.
Degrees
- M.D. Medicine
- University of Arizona, Tucson, Arizona, United States
Work Experience
- Southern Arizona VA Healthcare System (2003 - Ongoing)
Awards
- 2017 SAVAHCS Supervisor of the Year
- Southern Arizona VA Healthcare System, Spring 2018
Licensure & Certification
- License, Arizona Medical Board (2001)
- Board Certification, American Board of Psychiatry and Neurology (2003)
Interests
Teaching
anxiety disorders, sleep disorders, post traumatic stress disorder
Courses
No activities entered.
Scholarly Contributions
Journals/Publications
- Kumet, R., & Gelenberg, A. J. (2005). The effectiveness of generic agents in psychopharmacologic treatment.. Essential psychopharmacology, 6(2), 104-11.More infoIn order to win FDA approval, generic drugs must demonstrate bioequivalence, namely the ability to achieve blood levels similar to those of the innovator ones on which they are based. They must have the same active ingredients, be identical in strength, dosage form, and route of administration, and be manufactured under strict FDA standards. Because basic efficacy and safety studies are not required, their cost is significantly lower. However, there can be important differences between the innovator drugs and generics, as well as among the generics themselves. More research needs to be done to establish true comparability.
- Kumet, R., & Freeman, M. P. (2002). Clozapine and tardive dyskinesia.. The Journal of clinical psychiatry, 63(2), 167-8. doi:10.4088/jcp.v63n0213d
